In other in vitro studies, the addition of IPH2101, a clinical anti-KIR antibody, increased NK cell cytotoxicity against HLA-C positive acute myeloid leukemia and lymphoma cells (66, 67). The gene discussed is KIR3DL1; the disease is acute myeloid leukemia.